News

Sanofi-Aventis has signed a binding agreement for the acquisition of Fovea Pharmaceuticals (Fovea) a privately held French research and development biopharmaceutical company, focused on ocular diseases. Under the

Sciele Pharma and Addrenex Pharmaceuticals have announced that Addrenex has submitted a supplemental New Drug Application (sNDA) to the FDA for Clonicel (modified-release clonidine) to treat attention deficit

Sanofi-Aventis and Merrimack Pharmaceuticals have announced a global collaboration and licensing agreement on MM-121, a first-in-class, fully human monoclonal antibody designed to block signaling of the ErbB3 (HER3)

Cell Therapeutics (CTI) has announced that in a study from Brown University, patients with cancer of the lower esophagus demonstrated a high rate of complete remission (CR) when

Onset Therapeutics has launched BenzEFoam (benzoyl peroxide) 5.3% Emollient Foam, the first prescription foam formulation of benzoyl peroxide. BenzEFoam Emollient Foam is indicated for the topical treatment of

Advaxis’s Vaccine candidate ADXS11-001, in phase I trial has shown 36 month survival in 3 of the 13 evaluable patients treated with the cancer vaccine (ADXS11-001), indicating the

US Patent and Trademark Office has allowed claims covering the approved administration of BioMarin’s Kuvan (sapropterin dihydrochloride) with food, based on the discovery that food increases the bioavailability

HRA Pharma has announced that ellaOne (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the UK via local HRA teams. HRA

Provectus has initiated a phase 1 study of PV-10 for liver cancer. The study will enroll up to six subjects with cancer metastatic to the liver or with